Abstract
Background Different platforms were used to develop vaccines against SARS-CoV-2 which were instrumental in bringing an end to the pandemic. Nevertheless, long term efficacy and safety profiles of the various vaccine types is still being investigated. The current trial aimed to assess the safety and immunogenicity of the Gam-COVID-Vac combined vector vaccine against SARS-CoV-2-induced coronavirus infection up to 6 months post vaccination.
Methods In this randomized, double-blind, placebo-controlled trial, study participants ≥18 years of age with no prior SARS-COV-2 infection or vaccination were randomized (3:1) to receive the heterologous recombinant human adenovirus-vectored vaccines serotypes 26 and 5 or placebo. Immunogenicity was determined based on quantitative IgG antibodies (Abs) to viral S and N proteins, virus-neutralizing Abs (VNA), seroconversion rates, and S protein-specific CD4 and CD8 T cell responses.
Results A total of 990 participants were randomized to the vaccine (n=74) and placebo (n=246) groups. Overall incidence of Adverse events (AEs) was 1844 (81.5%) in the vaccine and 501 in placebo (82.1%) groups, the majority being in the mild/moderate categories. Two doses of vaccine induced VNA in 100% of participants on Day 42, with geometric mean ratio (GMR) reaching maximum at 120 days with average 24.14 (p<0.001). Vaccine group showed a very significant GMR for quantitative IgG to S protein. Difference in seroconversion rates was also significant with 90.0%, 83.7% and 78.9% on days 42, 120 and 180 (p<0.001 at all three points). A significant rise in the median of S protein-specific CD4+ and CD8+ T-lymphocytes with a robust IFN-γ response was evident after 28 days compared to baseline. Long-term follow-up demonstrated persistent and significant CD8+ T cell and IFN-γ responses at 120 days (p=0.049 and 0.039, respectively) compared to placebo group.
Conclusion Gam-COVID-Vac vaccine showed a good safety profile and induced strong and durable humoral and cellular immune responses. The viral-specific CD8+ T cell response appears to be more durable following vaccination than CD4+ T cell counterpart. Importantly, there was no evidence of any severe or persistent AEs in vaccinees suggestive of long COVID syndrome, emphasizing the safety of this heterologous prime-boost vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04656613
Funding Statement
The Global Sponsor (outside of United Arab Emirates): Human Vaccine LLC The Local Sponsor in United Arab Emirates: Aurugulf Health Investment Vaccine Development Company: Russian Ministry of Healthcare FGBU N.F. Gamaleya Scientific Research Center of Epidemiology and Microbiology. The sponsors had no role in the conduct of the trial or analysis of the data collected from volunteers or in the preparation of the manuscript for publication. This study was also funded in part by a grant from Zayed Center for Health Sciences (#31M493), Office of Research and Sponsored Projects, United Arab Emirates University, to BKa-R.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by the UAE Department of Health Central Ethics Committee, acting as the Local Ethics Committee (LEC; permission number DOH/CVDC/2020/2256 dated November 11, 2020), and the UAE Ministry of Health; Regulatory Committee at Ministry of Health and Prevention (RCMOHAP) permission: No. DSS-AOM-52/AMD001 dated December 14, 2020.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript